Amphastar Pharma (AMPH) Reports Q1 Loss of 1c/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Needham Starts NeoVolta (NEOV) at Buy
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
Jefferies Remains Bullish Following Amphastar Pharma's (AMPH) Strong Q1
May 14, 2015 10:27 AM EDTJefferies maintains a Buy rating on Amphastar Pharmaceuticals (NASDAQ: AMPH), and raised the price target to $19.00 (from $18.00), after a strong Q1. Analyst David Steinberg said that the strong Q1 was driven by a better than expected top line.
Steinberg commented on AMPH, saying, "Posting sales of $27.1M (+37% Y/Y), AMPHs base IMS injectables business contributed to half of the Q1 rev upside relative to our est, largely reflecting price... More
